Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Disentangling the Effects of HLA DRB115:01 and DQB106:02 to Establish the True HLA Risk Allele for Inhibitor Development in the Treatment of Hemophilia A

Vincent P. Diego, PhD, Bernadette W. Luu, B.S., M.T. (CLS), Alexis Garza, B.S., Marco Hofmann, M.S., Marcio A. Almeida, PhD, Jerry S. Powell, MD, Long V. Dinh, PhD, Raja Rajalingam, PhD, Juan M Peralta, M.S., Satish Kumar, PhD, Eli Fine, PhD, Joanne E. Curran, PhD, Miguel A. Escobar, MD, Sarah Williams-Blangero, PhD, Eugene Maraskovsky, PhD, John Blangero, PhD, Tom E. Howard, MD, PhD

Blood (2020) 136 (Supplement 1): 1–2.

https://doi.org/10.1182/blood-2020-142716

Published: 2020

Journal Articles

N-Linked Glycans on Therapeutic Factor VIII (FVIII) Proteins Attenuate Immunogenicity Potential: Evidence from Independent HLA-Class-II/FVIII (HLAcII/FVIII) Peptidomes

Vincent P. Diego, PhD, Bernadette W. Luu, B.S., M.T. (CLS), Hari Movva, B.S., Marco Hofmann, M.S., Marcio A. Almeida, PhD, Long V. Dinh, PhD, Jerry S. Powell, MD, Raja Rajalingam, PhD, Juan M Peralta, M.S., Henry Mead, M.B.A., M.P.H., Satish Kumar, PhD, Joanne E. Curran, PhD, Miguel A. Escobar, MD, Sarah Williams-Blangero, PhD, Eugene Maraskovsky, PhD, John Blangero, PhD, Tom E. Howard, MD, PhD

Blood (2020) 136 (Supplement 1): 29–30.

https://doi.org/10.1182/blood-2020-142493

Published: 2020

Journal Articles

The Dendritic Cell HLA-Class-II/Therapeutic Factor VIII (FVIII) Peptidome Is Influenced in Unanticipated Ways By the B-Domain of FVIII and the FVIII Chaperon Protein, Von Willebrand Factor: The Outrigger and Glycosylation-Umbrella (GUMB) Hypotheses

Tom E. Howard, MD, PhD, Bernadette W. Luu, B.S., M.T. (CLS), Marco Hofmann, M.S., Marcio A. Almeida, PhD, Satish Kumar, PhD, Long V. Dinh, PhD, Henry Mead, M.B.A., M.P.H., Jerry S. Powell, MD, Miguel A. Escobar, MD, Raja Rajalingam, PhD, Sarah Williams-Blangero, PhD, John Blangero, PhD, Maraskovsky Eugene, PhD, Vincent P. Diego, PhD

Blood (2019) 134 (Supplement_1): 161.

https://doi.org/10.1182/blood-2019-131727

Published: 2019

Journal Articles

On the Role of F8 Sequence Mismatch and Class-II Human Leukocyte Antigen Binding in the Development of Neutralizing Antibodies ("Inhibitors") Directed Against Therapeutic Factor VIII Proteins (tFVIIIs): Evidence from the PATH Study

Vincent P. Diego, PhD, Bernadette W. Luu, B.S., M.T. (CLS), Afshin Ameri, MD, Meera B. Chitlur, MD, Marcio A. Almeida, PhD, Karin Haack, PhD, Satish Kumar, PhD, Long V. Dinh, PhD, Henry Mead, M.B.A., M.P.H., Jerry S. Powell, MD, Miguel A. Escobar, MD, Raja Rajalingam, PhD, Sarah Williams-Blangero, PhD, Carol K. Kasper, MD, Laura Almasy, PhD, Shelley Cole, PhD, John Blangero, PhD, Tom E. Howard, MD, PhD

Blood (2019) 134 (Supplement_1): 2393.

https://doi.org/10.1182/blood-2019-132218

Published: 2019

Journal Articles

Genetics of Factor VIII Inhibitor Development in Hemophilia Patients: Novel Statistical Approaches in the PATH Study

Vincent P. Diego, PhD, Marcio A. Almeida, PhD, Bernadette W. Luu, BS, MT/CLS, Karin Haack, PhD, Meera B. Chitlur, MD, Afshin Ameri, MD, Long V. Dinh, PhD, Raja Rajalingam, PhD, Jerry S. Powell, MD, John Blangero, PhD, Laura Almasy, PhD, Shelley Cole, PhD, Tom E. Howard

Blood (2018) 132 (Supplement 1): 1199.

https://doi.org/10.1182/blood-2018-99-120021

Published: 2018

Journal Articles

The Role of Class II Human Leukocyte Antigens (cII-HLAs) in Determining the Immunogenic Potential of Therapeutic Factor VIII Proteins in Hemophilia Patients: The "Gate Keeper" Hypothesis

Vincent P. Diego, PhD, Bernadette W. Luu, BS, MT/CLS, Marco Hofmann, MS, Marcio A. Almeida, PhD, Jose Antonio G. Hernandez, PhD, Juan Peralta, MS, Joanne Curran, PhD, Jerry S. Powell, MD, Raja Rajalingam, PhD, Long V. Dinh, PhD, Sarah Williams-Blangero, PhD, Miguel A Escobar, MD, Eugene Maraskovsky, PhD, John Blangero, PhD, Tom E. Howard

Blood (2018) 132 (Supplement 1): 5022.

https://doi.org/10.1182/blood-2018-99-115537

Published: 2018

Journal Articles

Donor KIR3DL1 and HLA-B Allotypes Control Leukemia Relapse After Allogeneic Hematopoietic Stem Cell Transplantation

Fabio Giglio, MD, Ted A. Gooley, PhD, Jeffrey M Venstrom, MD, Meighan M Gallagher, LiHua Hou, PhD, Carolyn K Hurley, PhD, Tatiana Lebedeva, MD, PhD, Harriet Noreen, CHS, Raja Rajalingam, PhD, Elaine F Reed, PhD, Neng Yu, MD, Cynthia Vierra-Green, MS, Michael D Haagenson, MS, Mari Malkki, PhD, Effie W. Petersdorf, MD, Stephen Spellman, MBS, Katharine C. Hsu, MD, PhD

Blood (2012) 120 (21): 349.

https://doi.org/10.1182/blood.V120.21.349.349

Published: 2012

NARROW

Disentangling the Effects of HLA DRB115:01 and DQB106:02 to Establish the True HLA Risk Allele for Inhibitor Development in the Treatment of Hemophilia A

N-Linked Glycans on Therapeutic Factor VIII (FVIII) Proteins Attenuate Immunogenicity Potential: Evidence from Independent HLA-Class-II/FVIII (HLAcII/FVIII) Peptidomes

The Dendritic Cell HLA-Class-II/Therapeutic Factor VIII (FVIII) Peptidome Is Influenced in Unanticipated Ways By the B-Domain of FVIII and the FVIII Chaperon Protein, Von Willebrand Factor: The Outrigger and Glycosylation-Umbrella (GUMB) Hypotheses

On the Role of F8 Sequence Mismatch and Class-II Human Leukocyte Antigen Binding in the Development of Neutralizing Antibodies ("Inhibitors") Directed Against Therapeutic Factor VIII Proteins (tFVIIIs): Evidence from the PATH Study

Genetics of Factor VIII Inhibitor Development in Hemophilia Patients: Novel Statistical Approaches in the PATH Study

The Role of Class II Human Leukocyte Antigens (cII-HLAs) in Determining the Immunogenic Potential of Therapeutic Factor VIII Proteins in Hemophilia Patients: The "Gate Keeper" Hypothesis

Donor KIR3DL1 and HLA-B Allotypes Control Leukemia Relapse After Allogeneic Hematopoietic Stem Cell Transplantation

Email alerts

ASH Publications

American Society of Hematology

Disentangling the Effects of HLA DRB1*15:01 and DQB1*06:02 to Establish the True HLA Risk Allele for Inhibitor Development in the Treatment of Hemophilia A

N-Linked Glycans on Therapeutic Factor VIII (FVIII) Proteins Attenuate Immunogenicity Potential: Evidence from Independent HLA-Class-II/FVIII (HLAcII/FVIII) Peptidomes

The Dendritic Cell HLA-Class-II/Therapeutic Factor VIII (FVIII) Peptidome Is Influenced in Unanticipated Ways By the B-Domain of FVIII and the FVIII Chaperon Protein, Von Willebrand Factor: The Outrigger and Glycosylation-Umbrella (GUMB) Hypotheses

On the Role of F8 Sequence Mismatch and Class-II Human Leukocyte Antigen Binding in the Development of Neutralizing Antibodies ("Inhibitors") Directed Against Therapeutic Factor VIII Proteins (tFVIIIs): Evidence from the PATH Study

Genetics of Factor VIII Inhibitor Development in Hemophilia Patients: Novel Statistical Approaches in the PATH Study

The Role of Class II Human Leukocyte Antigens (cII-HLAs) in Determining the Immunogenic Potential of Therapeutic Factor VIII Proteins in Hemophilia Patients: The "Gate Keeper" Hypothesis

Donor KIR3DL1 and HLA-B Allotypes Control Leukemia Relapse After Allogeneic Hematopoietic Stem Cell Transplantation

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only

Disentangling the Effects of HLA DRB115:01 and DQB106:02 to Establish the True HLA Risk Allele for Inhibitor Development in the Treatment of Hemophilia A